Group 1 - Phathom Pharmaceuticals, Inc. announced a public offering of 6,875,000 shares of common stock priced at $16.00 per share, along with pre-funded warrants for 1,250,078 shares priced at $15.999 each, aiming for gross proceeds of approximately $130 million before expenses [1][2] - The offering is expected to close on or about January 9, 2026, pending customary closing conditions [1] - The underwriters have a 30-day option to purchase an additional 1,218,761 shares at the public offering price [1] Group 2 - The net proceeds from the offering will be used for general corporate purposes, including working capital and expenses related to commercialization and research and development [2] - Guggenheim Securities and Cantor are acting as joint bookrunning managers, with Raymond James, Needham & Company, H.C. Wainwright & Co., and Craig-Hallum serving as co-managers for the offering [2] Group 3 - Phathom Pharmaceuticals focuses on developing and commercializing novel treatments for gastrointestinal diseases, including the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker [5] - Vonoprazan is marketed in the U.S. under the brand name VOQUEZNA® for various gastrointestinal conditions, including heartburn and H. pylori infection [5]

Company Overview - Triton International Limited is the world's largest lessor of intermodal freight containers, with a fleet exceeding 7 million twenty-foot equivalent units (TEU) of owned and managed containers [8]. Offering Details - The company announced the pricing of an underwritten offering of 7,000,000 Series G Cumulative Redeemable Perpetual Preference Shares at a liquidation preference of $25.00 per share, resulting in gross proceeds of $175,000,000 [1]. - The net proceeds from the offering will be used for general corporate purposes, including the purchase of containers, payment of dividends, and repayment or repurchase of outstanding indebtedness [2]. - The offering is expected to close on January 12, 2026, subject to customary closing conditions, and the Series G Preference Shares will be listed on the New York Stock Exchange under the symbol "TRTN PRG" [2]. Management and Underwriters - Wells Fargo Securities, LLC, BofA Securities, Inc., Morgan Stanley & Co. LLC, RBC Capital Markets, LLC, and UBS Investment Bank are acting as joint book-running managers for the offering, while Brookfield Capital Solutions, Huntington Securities, Inc., and Regions Securities LLC are co-managers [2].

Core Viewpoint - Conavi Medical Corp. is conducting a public offering of common shares and pre-funded common share purchase warrants to raise between $12 million and $15 million for regulatory clearance and market release of its Novasight Hybrid system, along with working capital needs [2][3][6]. Group 1: Offering Details - The offering consists of a minimum of 26,666,667 and a maximum of 33,333,333 securities priced at $0.45 per common share or $0.44999 per pre-funded warrant [2]. - Each pre-funded warrant allows the holder to acquire one common share at an exercise price of $0.00001, with no expiration and can be exercised on a cashless basis [2]. - The offering may be completed in one or more tranches, with an expected initial closing date around January 13, 2026, subject to regulatory approvals [6]. Group 2: Use of Proceeds - The net proceeds from the offering will be used to obtain US FDA 510(k) clearance for the Novasight Hybrid system and to facilitate a targeted market release in the United States [3]. - Additional proceeds will be allocated for working capital and general corporate purposes [3]. Group 3: Agent and Fees - The company will pay the agent, Bloom Burton Securities Inc., a cash fee of 6.5% of the gross proceeds and grant compensation options equal to 6.5% of the total number of securities issued [7]. - A reduced cash commission of 3.25% will apply for certain purchasers on a president's list, with no compensation options for those sales [7]. Group 4: Regulatory Filings - An amended and restated final short form prospectus was filed on January 7, 2026, with securities regulatory authorities in Alberta, British Columbia, and Ontario [5]. - The offering is subject to customary closing conditions, including necessary regulatory and stock exchange approvals [6]. Group 5: Company Overview - Conavi Medical focuses on designing, manufacturing, and marketing imaging technologies for minimally invasive cardiovascular procedures [12]. - The Novasight Hybrid system combines intravascular ultrasound and optical coherence tomography into a single device, enabling simultaneous imaging of coronary arteries [12].

Core Viewpoint - Conavi Medical Corp. is conducting a public offering of common shares and pre-funded common share purchase warrants to raise between $12 million and $15 million for regulatory clearance and market release of its Novasight Hybrid system, along with working capital needs [2][3]. Offering Details - The offering consists of a minimum of 26,666,667 and a maximum of 33,333,333 securities priced at $0.45 per common share or $0.44999 per pre-funded warrant [2]. - Each pre-funded warrant allows the holder to acquire one common share at an exercise price of $0.00001, with no expiration and can be exercised on a cashless basis [2]. Use of Proceeds - The net proceeds from the offering will be used to obtain US FDA 510(k) clearance for the Novasight Hybrid system and to support a targeted market release in the United States, as well as for working capital and general corporate purposes [3]. Regulatory and Closing Information - The offering is expected to close on or about January 13, 2026, subject to customary closing conditions and necessary regulatory approvals [6]. - An amended and restated final short form prospectus was filed on January 7, 2026, which must be approved before any sale of securities [5]. Agent Compensation - The company will pay the agent a cash fee of 6.5% of the gross proceeds and grant compensation options equal to 6.5% of the total number of securities issued [7]. - A reduced cash commission of 3.25% will apply for certain purchasers on a president's list, with no compensation options for those sales [7]. Company Overview - Conavi Medical focuses on designing, manufacturing, and marketing imaging technologies for minimally invasive cardiovascular procedures, with its Novasight Hybrid system being the first to combine intravascular ultrasound and optical coherence tomography [12].

Core Viewpoint - Bright Minds Biosciences Inc. has announced a public offering of 1,945,000 common shares at a price of $90.00 per share, aiming for gross proceeds of $175,050,000 to fund clinical trials and research initiatives [1][3]. Group 1: Offering Details - The public offering consists of 1,945,000 common shares priced at $90.00 each, with expected gross proceeds of $175,050,000 [1]. - The underwriters have a 30-day option to purchase an additional 291,750 common shares at the public offering price [1]. - The closing of the offering is anticipated on January 9, 2026, pending customary closing conditions [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized to fund future clinical trials for drug candidates targeting absence seizures, developmental and epileptic encephalopathies (DEE), and Prader-Willi Syndrome [3]. - The funds will also support the initiation of phase 1 clinical trials for BMB-105 and additional research and development for earlier phase programs, along with general corporate and working capital purposes [3]. Group 3: Regulatory and Compliance - The company has filed a shelf registration statement on Form F-3 with the U.S. Securities and Exchange Commission (SEC), which became effective on September 2, 2025 [4]. - The offering is being conducted solely through a prospectus and a prospectus supplement that are part of the registration statement [4]. Group 4: Company Overview - Bright Minds is a biotechnology company focused on developing innovative treatments for neurological and psychiatric disorders, with a pipeline that includes novel compounds targeting key brain receptors [7]. - The company aims to deliver breakthrough therapies for conditions with high unmet medical needs, including epilepsy and depression [7][8].

FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that it intends to offer and sell, subject to market and other conditions, shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock, in an underwritten public offering. In additio ...

Mobix Labs (MOBX) announced the pricing of its previously announced public offering of 30,000,000 shares of its common stock for aggregate gross proceeds of approximately $6M, prior to deducting the placement agent’s fees and other offering expenses. The offering is expected to close on January 7, 2026, subject to satisfaction of customary closing conditions. D. Boral Capital is acting as the Sole Placement Agent for the offering. Mobix Labs, Inc. intends to use the net proceeds from the offering for worki ...

NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”) announces the launch of a public offering of common shares in the capital of the Company (the “Common Shares”) and, in lieu of Common Shares to investors that so choose, pre-funded warrants (the “Pre-Funded Warrants”) to purchase Common Shares, for aggregate gross proceeds of US$100 million (the “Offering”). In connection with the Offering, the Company intends to grant to th ...

IRVINE, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Mobix Labs, Inc. (Nasdaq: MOBX, “Mobix Labs” or the “Company”), a leading provider of advanced connectivity solutions, today announced that it intends to offer to sell shares of its common stock (or common stock equivalents in lieu thereof to purchase shares of its common stock) in a public offering. All of the securities to be sold in the offering are to be sold by the Company. The offering is subject to market and other conditions and there can be no assur ...

"Company†), a leading manufacturer of compound semiconductor wafer substrates, announced today the closing of its underwritten public offering of 8,163,265 shares of common stock at a price to the public of $12.25 per share, including the full exercise of the underwriters' option to purchase an additional 1,064,773 shares of the Company's common stock. The Company received total gross proceeds of approximately $100 milli. FREMONT, Calif.--(BUSINESS WIRE)--AXT, Inc. (NasdaqGS: AXTI) ("AXT†or the ...